Avenzo Therapeutics to be Acquired by Rallybio
Cooley advised Avenzo Therapeutics, a clinical-stage biotechnology company developing next-generation oncology therapies, on its agreement to be acquired by Rallybio, a clinical-stage biotechnology company.
The transaction was announced publicly in the following press release, which can be viewed here.
Rama Padmanabhan, Charles Bair, Wade Andrews, Rajdeep Bains, Marjorie O’Neill and Brittany Wightman led the Cooley corporate and M&A team advising Avenzo.
Charity Williams, Jonathan Kaufman, Noah Goldman, Kimberly Bolin, Mark Westwood, Alessandra Murata, Tony Guan, Ross Eberly, Jacob Lahana, Todd Gluth, Stephanie Gentile, Andrew Epstein, Allison Nostdahl, Natasha Leskovsek, Phil Mitchell, Sharon Connaughton, John DelMastro, Vittoria Rainone and Sunny Liu provided invaluable support.
About Cooley LLP
Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation.
Cooley has nearly 1,400 lawyers across 19 offices in the United States, Asia and Europe, and a total workforce of more than 3,000 people.
Related Contacts
This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as "Cooley"). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction, and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. When advising companies, our attorney-client relationship is with the company, not with any individual. This content may have been generated with the assistance of artificial intelligence (Al) in accordance with our Al Principles, may be considered Attorney Advertising and is subject to our legal notices.